Phio Pharmaceuticals Corp.
PHIONasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 |
| Operating income | −$9.2M | −$7.4M | −$10.8M | −$11.5M | −$13.5M | −$8.8M |
| Net income | −$8.7M | −$7.2M | −$10.8M | −$11.5M | −$13.3M | −$8.8M |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M | $15.7M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M | $2.7M |
| Equity | $20.1M | $4.7M | $7.7M | $10.8M | $21.9M | $13.0M |
| EPS (diluted) | $-1.45 | $-9.08 | $-46.76 | $-10.10 | $-12.43 | — |
| Shares out. | 4.8M | 4.6M | 1.2M | 13.5M | 13.5M | 2.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −43.2%
- Return on assets
- −40.5%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 6.2%
- Debt / equity
- 0.07×
- Book value / share
- $4.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −3.3%clean
- Piotroski F-Score
- 3/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Cvi Investments, Inc.Passive (13G)Feb 17, 2026
- Intracoastal Capital, LlcPassive (13G)Feb 13, 2026
- Orca Capital AgPassive (13G)Dec 11, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lockshin CurtisDirector | Feb 5, 2026 | Grant | 16,600 | $0.00 |
| Freeman Jonathan EDirector | Feb 5, 2026 | Grant | 16,600 | $0.00 |
| Deming David HDirector | Feb 5, 2026 | Grant | 23,800 | $0.00 |
| Carson Lisa CabottOfficer — Chief Financial Officer | Feb 5, 2026 | Grant | 47,000 | $0.00 |
| Bradford Patricia ADirector | Feb 5, 2026 | Grant | 18,500 | $0.00 |
| Bitterman Robert JOfficer — Chairman, Pres. & CEO | Feb 5, 2026 | Grant | 120,000 | $0.00 |
| Bitterman Robert JOfficer — Chairman, Pres. & CEO | Dec 31, 2025 | Buy | 5,000 | $1.03 |
| Bitterman Robert JOfficer — Chairman, Pres. & CEO | Dec 23, 2025 | Buy | 5,000 | $1.02 |
| Bitterman Robert JOfficer — Chairman, Pres. & CEO | Nov 21, 2025 | Buy | 5,000 | $1.14 |
| Bitterman Robert JOfficer — Chairman, Pres. & CEO | Nov 18, 2025 | Buy | 5,000 | $1.27 |
| Deming David HDirector | Sep 11, 2025 | Grant | 14,000 | $0.00 |
| Lockshin CurtisDirector | Sep 11, 2025 | Grant | 16,200 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 331,567 | 1.9 | -29.4% |
| Apr 30, 2026 | 469,570 | 4.2 | -9.8% |
| Apr 15, 2026 | 520,525 | 3.0 | -9.0% |
| Mar 31, 2026 | 571,887 | 1.7 | -2.4% |
| Mar 13, 2026 | 585,794 | 1.2 | +10.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Entered a material agreementApr 8, 2026
- Other material eventMar 30, 2026
- Results of operationsMar 5, 2026
- Director / officer changeFeb 18, 2026
- Other material eventFeb 10, 2026
- Other material eventJan 20, 2026
- Other material eventDec 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QMay 7, 2026
- 8-KFORM 8-KMay 7, 2026
- 8-KFORM 8-KApr 8, 2026
- 424B5PROSPECTUS SUPPLEMENTApr 8, 2026
- 8-KFORM 8-KMar 30, 2026
- 10-KFORM 10-KMar 5, 2026
- 8-KFORM 8-KMar 5, 2026
- 8-KFORM 8-KFeb 18, 2026
- SCHEDULE 13G/AFeb 17, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 8-KFORM 8-KFeb 10, 2026
- 4Feb 6, 2026
- 4Feb 6, 2026
- 4Feb 6, 2026
- 4Feb 6, 2026